海尔生物
(688139)
| 流通市值：124.07亿 | | | 总市值：124.07亿 |
| 流通股本：3.18亿 | | | 总股本：3.18亿 |
| 报告期 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,270,455,870.9 | 686,668,622.18 | 2,864,044,617.29 | 2,075,274,671.51 |
| 营业收入 | 1,270,455,870.9 | 686,668,622.18 | 2,864,044,617.29 | 2,075,274,671.51 |
| 二、营业总成本 | 1,034,950,299.72 | 557,268,271.77 | 2,293,396,024.59 | 1,641,257,015.03 |
| 营业成本 | 613,796,745.2 | 336,351,587.42 | 1,484,880,539.76 | 1,095,594,661.45 |
| 税金及附加 | 11,684,386.05 | 5,968,665.04 | 22,599,966.94 | 16,160,969.24 |
| 销售费用 | 168,807,126.2 | 80,360,225.34 | 348,370,345.86 | 238,609,885.42 |
| 管理费用 | 93,716,330.74 | 45,572,426.09 | 165,354,502.35 | 112,970,786.5 |
| 研发费用 | 157,574,507.09 | 80,011,141.6 | 292,470,141.2 | 211,246,026.69 |
| 财务费用 | -10,628,795.56 | 9,004,226.28 | -20,279,471.52 | -33,325,314.27 |
| 其中:利息费用 | 1,877,762.2 | 888,122.9 | 2,685,008.74 | 1,880,060.05 |
| 其中:利息收入 | 14,578,931.76 | 6,774,013.3 | 20,299,595.43 | 15,450,024.47 |
| 加:公允价值变动收益 | 1,459,949.22 | 319,226.22 | -7,007,496.25 | -6,299,452.72 |
| 加:投资收益 | 58,134,146.01 | 13,015,767.85 | 74,721,447.95 | 56,181,707.06 |
| 资产处置收益 | -2,062,769.54 | - | -312,748.52 | 594,477.54 |
| 资产减值损失(新) | -1,520,953.03 | 545,754.01 | -5,410,210.13 | -2,223,189.11 |
| 信用减值损失(新) | -431,240.09 | 47,880.39 | -1,115,799.29 | 805,423.21 |
| 其他收益 | 20,940,129.35 | 8,013,605.59 | 44,156,408.06 | 31,382,446.02 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 312,024,833.1 | 151,342,584.47 | 675,680,194.52 | 514,459,068.48 |
| 加:营业外收入 | 1,309,461 | 677,842.13 | 3,135,162.75 | 1,830,275.31 |
| 减:营业外支出 | 6,069,189.79 | 26,898.42 | 3,479,274.89 | 192,046.76 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 307,265,104.31 | 151,993,528.18 | 675,336,082.38 | 516,097,297.03 |
| 减:所得税费用 | 23,053,475.27 | 12,483,714.67 | 63,362,053.42 | 51,553,792.53 |
| 六、净利润 | 284,211,629.04 | 139,509,813.51 | 611,974,028.96 | 464,543,504.5 |
| 持续经营净利润 | 284,211,629.04 | 139,509,813.51 | 611,974,028.96 | 464,543,504.5 |
| 归属于母公司股东的净利润 | 278,462,841.61 | 137,535,031.82 | 600,791,263.18 | 461,446,373.79 |
| 少数股东损益 | 5,748,787.43 | 1,974,781.69 | 11,182,765.78 | 3,097,130.71 |
| (一)基本每股收益 | 0.88 | 0.43 | 1.89 | 1.46 |
| (二)稀释每股收益 | 0.88 | 0.43 | 1.89 | 1.46 |
| 八、其他综合收益 | -29,978,428.73 | 98,055.44 | -30,441,133.61 | 2,214,447.36 |
| 归属于母公司股东的其他综合收益 | -29,978,428.73 | 98,055.44 | -30,441,133.61 | 2,214,447.36 |
| 九、综合收益总额 | 254,233,200.31 | 139,607,868.95 | 581,532,895.35 | 466,757,951.86 |
| 归属于母公司股东的综合收益总额 | 248,484,412.88 | 137,633,087.26 | 570,350,129.57 | 463,660,821.15 |
| 归属于少数股东的综合收益总额 | 5,748,787.43 | 1,974,781.69 | 11,182,765.78 | 3,097,130.71 |
| 公告日期 | 2023-08-30 | 2023-04-26 | 2023-03-29 | 2022-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |